Moolec Science S.A.
MLECWHealthcare|Biotechnology|KY
$0.01
+0.00 (+0.01%)
DCF Value
$549.06
Cash / Share
$1.40
Financials
Financial Snapshot
Market Cap
$76.2K
Enterprise Value
$246.2M
Revenue (TTM)
$7.8M
Net Income (TTM)
-$8.3M
Cash & Investments
$1.1M
Net Cash
-$65.4M
Free Cash Flow (TTM)
-$6.1M
Operating CF (TTM)
-$5.7M
Debt/Equity
-3.74
Cash Runway & Burn Rate
Cash on Hand
$1.1M
Quarterly Burn
$1.4M
Monthly Burn
$474.8K
Est. Runway
~0.8 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $337.6K | $1.1M | $2.8M | $5.4M | $9.0M | $1.1M | |
| Operating Cash Flow | -$8.8K | -$1.9M | -$7.5M | -$9.3M | -$24.5M | -$5.7M | |
| Free Cash Flow | -$8.8K | -$1.9M | -$7.7M | -$9.5M | -$30.1M | -$6.1M | |
| Capital Expenditure | $0.00 | $0.00 | -$179.2K | -$158.3K | -$5.7M | -$420.0K | |
| Financing Cash Flow | $14.5K | $139.0M | $11.3M | $11.7M | $13.1M | $5.9M |
R&D Spending
R&D (TTM)
$1.6M
R&D Intensity
20.3%
R&D Growth vs Prior
-82.8%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $905.0K | $5.6M | $333.6M | $7.8M | |
| R&D Expense | $0.00 | $985.2K | $1.3M | $1.8M | $9.2M | $1.6M | |
| R&D % of Revenue | — | — | 149.1% | 31.5% | 2.8% | 20.3% | |
| SG&A | $13.8K | $2.6M | $47.7M | $7.2M | $115.2M | $6.3M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $905.0K | $5.6M | $333.6M | $7.8M | |
| Cost of Revenue | $0.00 | $0.00 | $1.0M | $5.2M | $219.6M | $8.5M | |
| Gross Profit | $0.00 | $0.00 | -$143.3K | $472.6K | $114.0M | -$639.5K | |
| R&D | $0.00 | $985.2K | $1.3M | $1.8M | $9.2M | $1.6M | |
| SG&A | $13.8K | $2.6M | $47.7M | $7.2M | $115.2M | $6.3M | |
| Operating Income | -$13.8K | -$1.7M | -$6.7M | -$9.0M | -$10.5M | -$9.1M | |
| Interest Expense | $0.00 | $2.1K | $160.0K | $1.2M | $41.8M | $2.2M | |
| Pretax Income | -$13.8K | -$93.8K | -$52.0M | -$8.3M | -$170.0M | -$8.6M | |
| Net Income | -$13.8K | -$4.5M | -$51.8M | -$7.3M | -$111.5M | -$8.3M | |
| EPS (Diluted) | -0.00 | -0.26 | -1.50 | -0.19 | -17.25 | -0.22 | |
| EBITDA | -$13.8K | -$3.7M | -$51.7M | $14.1M | -$69.0M | -$5.2M | |
| Shares Out. (M) | 17.37 | 17.37 | 34.47 | 37.87 | 6.46 | 38.96 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $337.6K | $1.1M | $2.5M | $5.4M | $767.9K | $1.0M | |
| Short-Term Investments | $0.00 | $0.00 | $306.0K | $0.00 | $8.3M | $39.1K | |
| Total Current Assets | $581.7K | $1.1M | $5.3M | $13.7M | $31.2M | $9.2M | |
| Total Assets | $138.6M | $5.7M | $24.1M | $34.8M | $204.7M | $103.4M | |
| Total Current Liabilities | $861.9K | $4.1M | $12.6M | $8.2M | $236.1M | $61.9M | |
| Long-Term Debt | $0.00 | $0.00 | $99.0K | $11.7M | $19.6M | $12.0M | |
| Total Liabilities | $4.5M | $4.1M | $13.9M | $28.0M | $287.6M | $88.2M | |
| Stockholders' Equity | $134.1M | $1.6M | $10.1M | $6.8M | -$66.0M | $9.2M | |
| Retained Earnings | -$828.1K | -$6.8M | -$58.6M | -$65.9M | -$110.3M | -$44.6M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.8K | -$1.9M | -$7.5M | -$9.3M | -$24.5M | -$5.7M | |
| Capital Expenditure | $0.00 | $0.00 | -$179.2K | -$158.3K | -$5.7M | -$420.0K | |
| Free Cash Flow | -$8.8K | -$1.9M | -$7.7M | -$9.5M | -$30.1M | -$6.1M | |
| Investing Cash Flow | $0.00 | -$138.0M | -$2.3M | $134.9K | -$36.0M | -$270.2K | |
| Financing Cash Flow | $14.5K | $139.0M | $11.3M | $11.7M | $13.1M | $5.9M | |
| Issuance of Stock | $26.2K | $139.4M | $10.0M | $13.1M | $0.00 | $13.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$305.0K | -$926.9K | -$305.0K | |
| Net Debt Issuance | $295.0K | $0.00 | $1.3M | $10.9M | $23.3M | $4.8M | |
| Stock Based Comp. | $0.00 | $838.6K | $43.8M | $2.0M | $0.00 | $866.7K | |
| Net Change in Cash | $5.7K | $131.0K | $1.4M | $2.9M | -$52.2M | $228.4K |
Dilution Tracker
Shares Outstanding
11M
5-Year Share Growth
-62.8%
Stock Issuance (TTM)
$13.1M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 17.37 | 17.37 | 34.47 | 37.87 | 6.46 | 38.96 | |
| Change vs Prior % | — | 0.0% | 98.4% | 9.9% | -82.9% | 502.8% | |
| Stock Issuance | $26.2K | $139.4M | $10.0M | $13.1M | $0.00 | $13.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$305.0K | -$926.9K | -$305.0K | |
| Stock Based Comp. | $0.00 | $838.6K | $43.8M | $2.0M | $0.00 | $866.7K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | -15.8% | 8.4% | 34.2% | -8.2% | |
| Operating Margin % | — | — | -735.2% | -160.8% | -3.1% | -116.7% | |
| Net Margin % | — | — | -5722.2% | -130.0% | -33.4% | -105.7% | |
| EBITDA Margin % | — | — | -5717.0% | 251.3% | -20.7% | -66.5% | |
| FCF Margin % | — | — | -849.7% | -168.6% | -9.0% | -78.1% | |
| ROE % | -0.0% | -282.2% | -512.5% | -107.3% | 169.0% | 376.8% | |
| ROA % | -0.0% | -79.5% | -215.3% | -21.0% | -54.4% | -54.4% | |
| ROIC % | -0.0% | -99.3% | -47.3% | -26.9% | -5.3% | -5.3% | |
| R&D / Revenue % | — | — | 149.1% | 31.5% | 2.8% | 20.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 521.5% | 5830.7% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 429.8% | 24024.0% | |
| Operating Income | 0.0% | -12339.6% | -287.6% | -35.9% | -15.9% | |
| Net Income | 0.0% | -32698.9% | -1044.0% | 85.9% | -1424.3% | |
| EPS (Diluted) | 0.0% | -32400.0% | -476.9% | 87.3% | -8978.9% | |
| Operating Cash Flow | 0.0% | -21326.7% | -298.3% | -24.2% | -162.1% | |
| Free Cash Flow | 0.0% | -21326.7% | -307.8% | -23.4% | -217.3% | |
| R&D Expense | 0.0% | 0.0% | 37.0% | 31.3% | 421.2% | |
| SG&A Expense | 0.0% | 18942.8% | 1713.8% | -84.9% | 1505.4% | |
| Total Assets | 0.0% | -95.9% | 322.6% | 44.6% | 488.5% | |
| Book Value / Share | 0.0% | -98.8% | 217.5% | -38.6% | -7224.8% | |
| Debt | 0.0% | 0.0% | 2016.2% | 455.0% | 1581.6% | |
| Diluted Shares | 0.0% | 0.0% | 98.4% | 9.9% | -82.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High0.00 / 0.28 / 3.04
P/B-0.00
10Y Low / Med / High0.03 / 0.27 / 2.27
EV/EBITDAAt Loss
EV/Revenue0.74
10Y Low / Med / High0.74 / 1.93 / 3.17
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$549.06
Cash / Share
$1.40
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -262.50 | -0.81 | -0.05 | -0.22 | -0.00 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 3.04 | 0.28 | 0.00 | 0.00 | |
| P/B Ratio | 0.03 | 2.27 | 0.27 | 0.23 | -0.00 | -0.00 | |
| EV/EBITDA | -248.92 | -0.74 | -0.06 | 0.77 | -3.57 | -3.57 | |
| EV/Revenue | 0.00 | 0.00 | 3.17 | 1.93 | 0.74 | 0.74 |
Analyst Estimates & Quality
Altman Z-Score
-1.34
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 |
|---|---|---|
| Revenue | $77.3M | $130.8M |
| Net Income | $38.8M | $193.9M |
| EPS | $6.00 | $30.00 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Geography
| Segment | 2024 |
|---|---|
| ARGENTINA | $231.8M |
| BRAZIL | $17.7M |
| Europe Middle East And Africa Member | $7.9M |
| Latin America | $23.9M |
| North America | $30.1M |